Developing RNA-targeting medicines to treat previously incurable diseases
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.
WOBURN, Mass., Dec. 4, 2024 /PRNewswire/ — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with GSK. The alliance aims to advance the discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology.
Work with us
At Rgenta, our vision is aligned with one goal- to serve patients- by paving the way in precision medicine.
If you are bold, see the possibilities in front of you and strive to be impactful, we want to meet you!